Originally published July 26, 2023 2:00 pm PDT
The American Cancer Society (ACS) estimates that there will be 1,958,310 new cancer cases in the United States in 2023.
This represents a more than 11% increase from 2019, four years prior, when ACS data show there were 1,762,450 estimated cancer cases in the country.
The spike in cases from 2019 to 2023 is significant because the 2019 cancer rate only represents a 6% increase from 2015, when there were 1,658,370 estimated cases.
This means that the percent increase in cancer rate estimates in the U.S. between 2019 and 2023 is nearly double the percent increase between 2015 and 2019.
In 2020, the U.S. Food and Drug Administration authorized COVID-19 vaccines to be delivered to all 50 states, the District of Columbia, and Puerto Rico, in response to the coronavirus pandemic.
As of April 26, 2023, roughly 980 million COVID vaccine doses were distributed in the United States, according to Statista.
Coronavirus vaccines have so far been linked to 1,574,580 adverse event reports, according to data from the U.S. Centers for Disease Control and Prevention’s (CDC) Vaccine Adverse Event Reporting System (VAERS).
The vaccine that was first widely distributed in the country was Pfizer/BioNTech’s jab, which Pfizer’s own safety data show is linked to cancers like Kaposi Sarcoma.
Moreover, the cancer-promoting virus SV-40, which has the ability to transform normal cells into cancerous cells, was also recently discovered to be found in Pfizer’s vaccine.
In addition, a May study published in the journal Vaccines warned that “over-vaccination” with COVID vaccines might not only weaken the alleged protection provided by the vaccine, but also cause “autoimmune diseases,” induce heart disease, and “promote cancer growth.”
Moreover still, a February case report published in the peer-reviewed medical journal Cureus demonstrated a possible association between the COVID mRNA jab and a temporary, nearly five-fold rise in levels of an essential biomarker (CA-125) for detecting response to treatment and recurrence of certain cancers.
That case report presented a 79-year-old woman with a history of moderately-differentiated adenocarcinoma of the right adnexa (a type of cancer with moderate abnormal cell growth found in the reproductive organs or nearby tissues on the right side of the body) who had a temporary but significant increase in CA-125 levels after receiving the first dose of Pfizer’s COVID mRNA vaccine.
Her CA-125 levels had increased by roughly five times after vaccination, rising from 15.8 U/ml to 78.0 U/ml at her follow-up visit.
This means her cancer biomarker level had increased by 4.9 times, or 393.67%, after taking the COVID vaccine.
The CDC claims that COVID vaccines are “safe and effective.”
